Defining "poor mobilizer" in pediatric patients who need an autologous peripheral blood progenitor cell transplantation

Cytotherapy

Volumn 15, Issue 1, 2013, Pages 132-137

  Sevilla, Julián ^a,b   Guillén, María ^a,b   Castillo, Ana ^c   Prudencio, Marta ^a   González Vicent, Marta ^b   Lassaletta, Álvaro ^a   Cormenzana, María ^a   Ramírez, Manuel ^a   Pérez Martínez, Antonio ^b   Madero, Luis ^a,b   Díaz Pérez, Miguel Ángel ^b  

^a Servicio de Hemato Oncología   (Spain)

^b HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^c Servicio de Análisis Clínicos   (Spain)

Author keywords

Apheresis; Granulocyte colony stimulating factor; Hematopoietic progenitor cells; Mobilization; Peripheral blood; Peripheral blood stem cells; Poor mobilizers

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER PATIENT; CANCER RADIOTHERAPY; CD34 SELECTION; CELL COUNT; CHILD; CHILDHOOD CANCER; DRUG MEGADOSE; EWING SARCOMA; HUMAN; INFANT; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; STEM CELL MOBILIZATION;

EID: 84875413131     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2012.10.004     Document Type: Article

References (17)

1. Olivieri A, Marchetti M, Lemoli R, Tarella C, Iacone A, Lanza F, et al. Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: An analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo [published online ahead of print May 30, 2011]. Bone Marrow Transplant.
2. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, et al. Poor mobilization of hematopoietic stem cellsdefinitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant. 2010;16:490-9.
3. Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, Coluccia P, et al. Management of poor peripheral blood stem cell mobilization: Incidence, predictive factors, alternative strategies and outcome: A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci. 2009;41:33-7.
4. Sevilla J, González-Vicent M, Madero L, García- Sánchez F, Díaz MA. Large volume leukapheresis in small children: Safety profile and variables affecting peripheral blood progenitor cell collection. Bone Marrow Transplant. 2003; 31:263-7.
5. Merlin E, Zohar S, Jerôme S, Veyrat-Masson R, Marceau G, Paillard C, et al. Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: Do the advantages of pegfilgastrim really translate into clinical benefit? Bone Marrow Transplant. 2009;43:919-25.
6. Gertz MA. Current status of stem cell mobilization. Br J Haematol. 2010;150:647-62.
7. Keeney M, Chin-Yee I, Weir K. Single platform flow cytometric absolute CD34? cell counts based on the ISHAGE guidelines. Cytometry. 1998;34:61-70.
8. Mohty M, Duarte RF, Croockewit S, Hübel K, Kvalheim G, Russell N. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia. 2011;25:1-6.
9. ÖzkurtZN, Yegin ZA, Suyani E, Aki SZ, Acar K, Yagci M, et al. Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation. J Clin Apher. 2010;25:280-6.
10. Wang S, Nademanee A, Qian D, Dagis A, Park H, Fridey J, et al. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Transfusion. 2007; 47:2207-16.
11. Basak GW, Jaksic O, Koristek Z, Mikala G, Mayer J, Massazi T, et al. Identification of prognostic factors for plerixafor based hematopoietic stem cell mobilization. Am J Hematol. 2011;86:550-3.
12. Sevilla J, Schiavello E, Madero L, Pardeo M, Guggiari E, Baragaño M, et al. Priming of hematopoietic progenitor cells by plerixafor and filgastrim in children with previous failure of mobilization with chemotherapy and/or cytokine treatment. J Pediatr Hematol Oncol. 2012;34: 146-50.
13. Toledano H, Yahel A, Cohen IJ, Yaniv I, Stein J. Successful mobilization, harvest and transplant of peripheral blood stem cells using AMD3100 and G-CSF following high dose craniospinal irradiation for medulloblastoma in a young child. Pediatr Blood Cancer. 2010;54:613-5.
14. Cardenoux C, Demenocq F, Kanold J, Merlin E. Pegfilgastrim plus AMD 3100 for stem cell mobilization in children. Pediatric Blood Cancer. 2010;55:769.
15. Aabideen K, Anoop P, Ethell ME, Potter MN. The feasibility of plerixafor as a second-line stem cell mobilizing agent in children. J Pediatr Hematol Oncol. 2011;33:65-7.
16. Stephen K, Montgomery K, Bateman C, Calandra G, Shaw PJ. Successful mobilisation, harvest, and transplant of stem cells following AMD3100 in 3 paediatric patients: The Australian experience. Biol Blood Marrow Transplant. 2006;12:157.
17. Horwitz ME, Chute JP, Gasparetto C, Long GD, McDonald C, Morris A, et al. Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration [published online ahead of print Nov 14, 2011]. Bone Marrow Transplant. doi: 10.1038/bmt.2011.217.